Nisha Acharya, MD
Ophthalmology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Offices
- 2
Offices
2 locations · UCSF Medical Group Business Services · Regents of the University of California
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Acharya’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A86705 · Current
Licensed to practise in California · since 2004 · expires 2027-08-31 · University of California San Francisco School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Original Medicare doctor bills
$9,420
Medicare paid this office $9,420 for 41 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 32 | $4,496 | $105 |
| Imaging of retina | 21 | $953 | $37 |
Who their Medicare patients are
41 Original Medicare patients in 2024. Average age 71 · Women 73% · Also on Medicaid 34% · Health risk score 1.11. At or below the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 63%.
The office billed $50,059, Medicare allowed $13,107 and paid $9,420; for 99 services of 9 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 41 | 99 | 71 | 1.11 | $50,059 | $9,420 |
| 2023 | 37 | 125 | 72 | 0.95 | $56,630 | $10,466 |
| 2022 | 35 | 122 | 69 | 1.10 | $56,748 | $9,838 |
| 2021 | 34 | 117 | 69 | 1.35 | $56,640 | $10,104 |
| 2020 | 26 | 83 | 70 | 1.10 | $40,374 | $6,917 |
| 2019 | 29 | 87 | 68 | 1.55 | $45,791 | $7,734 |
| 2018 | 37 | 100 | 71 | 1.48 | $51,114 | $9,527 |
| 2017 | 35 | 87 | 68 | 1.33 | $45,524 | $8,438 |
| 2016 | 36 | 87 | 65 | 1.82 | $47,454 | $8,675 |
| 2015 | 31 | 83 | 64 | 1.10 | $42,653 | $8,234 |
| 2014 | 21 | 36 | 65 | 0.95 | $19,104 | $3,864 |
| 2013 | 32 | 119 | 67 | 0.94 | $47,272 | $9,922 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Return visit (30+ min) | 30 | $5,046 | $107 |
| Imaging of retina | 28 | $1,617 | $38 |
2022: 2 services
| Return visit (30+ min) | 30 | $5,238 | $103 |
| Imaging of retina | 24 | $1,364 | $38 |
2021: 3 services
| Return visit (30+ min) | 22 | $4,291 | $119 |
| Established patient complete exam of visual system | 14 | $1,473 | $92 |
| Imaging of retina | 19 | $1,134 | $37 |
2020: 2 services
| Established patient complete exam of visual system | 15 | $3,142 | $116 |
| Imaging of retina | 16 | $1,031 | $40 |
2019: 3 services
| Established patient complete exam of visual system | 22 | $4,331 | $111 |
| Established patient problem focused exam of visual system | 13 | $1,998 | $80 |
| Imaging of retina | 11 | $561 | $40 |
2018: 2 services
| Established patient complete exam of visual system | 33 | $7,068 | $116 |
| Imaging of retina | 16 | $768 | $40 |
2017: 2 services
| Established patient complete exam of visual system | 32 | $7,040 | $115 |
| Imaging of retina | 11 | $577 | $38 |
2016: 1 service
| Established patient complete exam of visual system | 30 | $6,365 | $110 |
2015: 2 services
| Established patient complete exam of visual system | 28 | $6,797 | $117 |
| Imaging of retina | 12 | $613 | $41 |
2014: 1 service
| Established patient complete exam of visual system | 15 | $2,429 | $121 |
2013: 2 services
| Established patient complete exam of visual system | 30 | $6,828 | $112 |
| Imaging of retina | 19 | $849 | $26 |
Money from drug and device companies
$21,459 in 2025
| 2025 | 2 | 12 | $20,001 | $21,459 |
| 2024 | 1 | 4 | $11,486 | $11,486 |
| 2023 | 2 | 4 | $10,575 | $10,699 |
| 2022 | 1 | 1 | None | $117 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Genentech USA | None | $14,953 | 10 payments
|
| Genentech | Susvimo | $6,506 | 2 payments
|
See all 12 published payments
| Genentech | Consulting · 2025-11-20 | None | $3,150 |
| Genentech USA | Meals · 2025-11-15 | None | $83 |
| Genentech USA | Consulting · 2025-11-15 | None | $7,350 |
| Genentech USA | Meals · 2025-11-15 | None | $83 |
| Genentech USA | Meals · 2025-11-15 | None | $73 |
| Genentech USA | Meals · 2025-07-31 | None | $52 |
| Genentech USA | Meals · 2025-07-31 | None | $120 |
| Genentech USA | Travel · 2025-07-31 | None | $224 |
| Genentech USA | Travel · 2025-07-31 | None | $452 |
| Genentech USA | Travel · 2025-07-31 | None | $371 |
| Genentech USA | Consulting · 2025-07-31 | None | $6,145 |
| Genentech | Consulting · 2025-07-02 | Susvimo | $3,356 |
See earlier years (2024, 2023, 2022)
2024: $11,486
| Genentech | Susvimo | $11,486 | 4 payments
|
2023: $10,699
| Genentech | Susvimo | $10,575 | 3 payments
|
| Bausch & Lomb Americas | Xipere | $124 | 1 payment
|
2022: $117
| Bausch & Lomb Americas | Xipere | $117 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| AbbVie Inc. · Humira · 2020 | Their institution | $14,577,771 |
| ABBVIE INC. · Adalimumab in Juvenile Idiopathic Arthritis-Associated Uveitis Stopping Trial (Adjust) · 2022 | Their institution | $6,770,322 |
| ABBVIE INC. · Adalimumab in Juvenile Idiopathic Arthritis-Associated Uveitis Stopping Trial (Adjust) · 2021 | Their institution | $6,708,234 |
| ABBVIE INC. · Adalimumab in Juvenile Idiopathic Arthritis-Associated Uveitis Stopping Trial (Adjust) · 2023 | Their institution | $4,845,872 |
| ABBVIE INC. · Adalimumab in Juvenile Idiopathic Arthritis-Associated Uveitis Stopping Trial (Adjust) · 2024 | Their institution | $27,695 |
| F. Hoffmann-La Roche AG · Evaluation of the Role of Interleukin-6 and Vascular Endothelial Growth Factor in Uveitic Macular Edema and Uveitis · 2025 | This clinician | $1,791 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 75.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1972544872
- Licence
- CA A86705California A86705: Current · expires 2027-08-31
- Trained
- University of California, San Francisco School of Medicine, 2000
- Group
- UCSF Medical Group Business Services · Regents of the University of California
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A867050
- Taxonomy
- Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 1635 Divisadero Street, Suite 625, Box 1821, San Francisco, CA, 94143
- NPI first listed
- 2006-06-10
- NPI last updated
- 2008-07-23
This is when the NPI record was last certified, not a medical board exam.